Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability.

@article{Gonalves2014DevelopmentOA,
  title={Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability.},
  author={Viviane M. Gonçalves and Waldely de Oliveira Dias and Ivana Barros Campos and Celia Liberman and Maria Elisabete Sbrogio-Almeida and Eliane Pereira da Silva and Celso P Cardoso and Mark R. Alderson and George Robertson and J. P. Maisonneuve and Andrea Tate and Porter W. Anderson and Richard Malley and Fernando Fratelli and Luciana C. C. Leite},
  journal={Vaccine},
  year={2014},
  volume={32 9},
  pages={1113-20}
}
Pneumococcal infections impose a large burden of disease on the human population, mainly in developing countries, and the current pneumococcal vaccines offer serotype-specific protection, but do not cover all pathogenic strains, leaving populations vulnerable to disease caused by non-vaccine serotypes. The pneumococcal whole cell vaccine is a low-cost strategy based on non-capsular antigens common to all strains, inducing serotype-independent immunity. Therefore, we developed the process for… CONTINUE READING
Highly Cited
This paper has 36 citations. REVIEW CITATIONS